Market research
5MC1.F Leap Therapeutics, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 73M
- P/E ratio
- Not available
- Analyst target
- 4.5
- Dividend yield
- 0.0%
- Beta
- 0.68
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
- ISIN
- US52187K1016
- Market cap
- 73M
- P/E ratio
- Not available
- Analyst target
- 4.5
- Dividend yield
- 0.0%
- Beta
- 0.68
About
About Leap Therapeutics, Inc
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 5MC1.F discussion.
5 years, 5 months ago
Leap Therapeutics, Inc is currently in a long term downtrend where the price is trading 24.8% below its 200 day moving average.
From a valuation standpoint, the stock is 94.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 73.4.
Leap Therapeutics, Inc's total revenue rose by inf% to $375K since the same quarter in the previous year.
Its net income has increased by 16.1% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 1.6% to $-6M since the same quarter in the previous year.
Based on the above factors, Leap Therapeutics, Inc gets an overall score of 3/5.